These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
23. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. Li J; Ding Z; Wang Z; Lu JF; Maity SN; Navone NM; Logothetis CJ; Mills GB; Kim J PLoS One; 2011; 6(12):e28840. PubMed ID: 22194926 [TBL] [Abstract][Full Text] [Related]
24. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173 [TBL] [Abstract][Full Text] [Related]
25. NF-κB and androgen receptor variant 7 induce expression of SRD5A isoforms and confer 5ARI resistance. Austin DC; Strand DW; Love HL; Franco OE; Grabowska MM; Miller NL; Hameed O; Clark PE; Matusik RJ; Jin RJ; Hayward SW Prostate; 2016 Aug; 76(11):1004-18. PubMed ID: 27197599 [TBL] [Abstract][Full Text] [Related]
26. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789 [TBL] [Abstract][Full Text] [Related]
27. Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. Zang T; Tamae D; Mesaros C; Wang Q; Huang M; Blair IA; Penning TM J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):342-355. PubMed ID: 27531846 [TBL] [Abstract][Full Text] [Related]
28. Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. Alyamani M; Li Z; Berk M; Li J; Tang J; Upadhyay S; Auchus RJ; Sharifi N Cell Chem Biol; 2017 Jul; 24(7):825-832.e6. PubMed ID: 28648378 [TBL] [Abstract][Full Text] [Related]
29. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301 [TBL] [Abstract][Full Text] [Related]
30. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells. Robitaille CN; Rivest P; Sanderson JT Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206 [TBL] [Abstract][Full Text] [Related]
31. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Mitsiades N; Sung CC; Schultz N; Danila DC; He B; Eedunuri VK; Fleisher M; Sander C; Sawyers CL; Scher HI Cancer Res; 2012 Dec; 72(23):6142-52. PubMed ID: 22971343 [TBL] [Abstract][Full Text] [Related]
32. Expression of androgen receptor and 5alpha-reductases in the human normal endometrium and its disorders. Ito K; Suzuki T; Akahira J; Moriya T; Kaneko C; Utsunomiya H; Yaegashi N; Okamura K; Sasano H Int J Cancer; 2002 Jun; 99(5):652-7. PubMed ID: 12115497 [TBL] [Abstract][Full Text] [Related]
33. Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Pouliot F; Rouleau M; Neveu B; Toren P; Morin F; Vélot L; Ding K; Caron P; Lacombe L; Lévesque É; Klotz L; Guillemette C J Urol; 2020 May; 203(5):940-948. PubMed ID: 31845837 [TBL] [Abstract][Full Text] [Related]
34. 5α-reduction of epitestosterone is catalysed by human SRD5A1 and SRD5A2 and increases androgen receptor transactivation. Schiffer L; Arlt W; Storbeck KH J Steroid Biochem Mol Biol; 2024 Jul; 241():106516. PubMed ID: 38582131 [TBL] [Abstract][Full Text] [Related]
35. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Mohler JL; Titus MA; Bai S; Kennerley BJ; Lih FB; Tomer KB; Wilson EM Cancer Res; 2011 Feb; 71(4):1486-96. PubMed ID: 21303972 [TBL] [Abstract][Full Text] [Related]
36. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707 [TBL] [Abstract][Full Text] [Related]
37. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells. Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564 [TBL] [Abstract][Full Text] [Related]
38. Profiles of 5α-Reduced Androgens in Humans and Eels: 5α-Dihydrotestosterone and 11-Ketodihydrotestosterone Are Active Androgens Produced in Eel Gonads. Yazawa T; Inaba H; Imamichi Y; Sekiguchi T; Uwada J; Islam MS; Orisaka M; Mikami D; Ida T; Sato T; Miyashiro Y; Takahashi S; Khan MRI; Suzuki N; Umezawa A; Kitano T Front Endocrinol (Lausanne); 2021; 12():657360. PubMed ID: 33833737 [TBL] [Abstract][Full Text] [Related]
39. Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice. Windahl SH; Andersson N; Börjesson AE; Swanson C; Svensson J; Movérare-Skrtic S; Sjögren K; Shao R; Lagerquist MK; Ohlsson C PLoS One; 2011; 6(6):e21402. PubMed ID: 21731732 [TBL] [Abstract][Full Text] [Related]
40. Targeting 5α-reductase for prostate cancer prevention and treatment. Nacusi LP; Tindall DJ Nat Rev Urol; 2011 May; 8(7):378-84. PubMed ID: 21629218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]